Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma - PubMed (original) (raw)
. 2003 Nov 20;22(52):8386-93.
doi: 10.1038/sj.onc.1207170.
Affiliations
- PMID: 14627979
- DOI: 10.1038/sj.onc.1207170
Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma
Teru Hideshima et al. Oncogene. 2003.
Abstract
Proteasome inhibitor PS-341 is one of the most promising novel agents against multiple myeloma (MM). We have previously shown that PS-341 inhibits IL-6 triggered phosphorylation of extracellular signal-regulated kinases (ERK) 1/2 (also known as p42/44 mitogen-activated protein kinases) in MM cells. In this study, we further examined whether clinically achievable concentrations of PS-341 could inhibit IL-6 triggered signaling cascades in MM. We found that PS-341 inhibited not only ERK, but also signal transducers and activators of transcription (STAT) 3 as well as Akt phosphorylation. Since gp130 (CD130) dimerizes and is phosphorylated after IL-6 binding to gp80 (IL-6 receptor), we hypothesized that gp130 could be involved in PS-341-induced blockade of signaling cascades mediating MM cell growth, survival, and drug resistance in the bone marrow (BM) microenvironment. In this study, we first demonstrate that PS-341 induces downregulation of gp130 in a time- and dose-dependent manner in vitro, prior to MM cell death. Conversely, downregulation of gp130 is completely abrogated by the pan-caspase inhibitor Z-VAD-FMK, suggesting that downregulation of gp130 is mediated via caspase activation. Z-VAD-FMK also abrogates the inhibitory effect of PS-341 on IL-6-triggered signaling cascades. Importantly, we demonstrate that phosphorylation of ERK, STAT3, and Akt in MM.1S cells induced by either exogenous IL-6 or by binding of MM cells to BM stromal cells is abrogated by PS-341. These studies, therefore, define another novel mechanism whereby PS-341 can overcome the growth and survival advantage in MM cells conferred by the BM milieu. Importantly, this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment.
Similar articles
- The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. Hideshima T, et al. Oncogene. 2001 Jul 27;20(33):4519-27. doi: 10.1038/sj.onc.1204623. Oncogene. 2001. PMID: 11494147 - Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver.
Graf D, Kohlmann C, Haselow K, Gehrmann T, Bode JG, Häussinger D. Graf D, et al. Hepatology. 2006 Nov;44(5):1206-17. doi: 10.1002/hep.21368. Hepatology. 2006. PMID: 17058237 - Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ. Voorhees PM, et al. Clin Cancer Res. 2007 Nov 1;13(21):6469-78. doi: 10.1158/1078-0432.CCR-07-1293. Clin Cancer Res. 2007. PMID: 17975159 - IL-6 signal transduction and its physiological roles: the signal orchestration model.
Kamimura D, Ishihara K, Hirano T. Kamimura D, et al. Rev Physiol Biochem Pharmacol. 2003;149:1-38. doi: 10.1007/s10254-003-0012-2. Epub 2003 Apr 5. Rev Physiol Biochem Pharmacol. 2003. PMID: 12687404 Review. - Characteristics, pathogenesis, and novel treatments for multiple myeloma.
San Miguel J. San Miguel J. J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S1-4. J Natl Compr Canc Netw. 2004. PMID: 19791422 Review.
Cited by
- Primed for Interactions: Investigating the Primed Substrate Channel of the Proteasome for Improved Molecular Engagement.
Loy CA, Trader DJ. Loy CA, et al. Molecules. 2024 Jul 17;29(14):3356. doi: 10.3390/molecules29143356. Molecules. 2024. PMID: 39064934 Free PMC article. Review. - IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?
Suzuki K, Yano S. Suzuki K, et al. Life (Basel). 2023 Nov 20;13(11):2229. doi: 10.3390/life13112229. Life (Basel). 2023. PMID: 38004369 Free PMC article. Review. - Steps towards a Multiple Myeloma Cure?
Gozzetti A, Bocchia M. Gozzetti A, et al. J Pers Med. 2022 Sep 3;12(9):1451. doi: 10.3390/jpm12091451. J Pers Med. 2022. PMID: 36143236 Free PMC article. - A 3D-Bioprinted Multiple Myeloma Model.
Wu D, Wang Z, Li J, Song Y, Perez MEM, Wang Z, Cao X, Cao C, Maharjan S, Anderson KC, Chauhan D, Zhang YS. Wu D, et al. Adv Healthc Mater. 2022 Apr;11(7):e2100884. doi: 10.1002/adhm.202100884. Epub 2021 Sep 23. Adv Healthc Mater. 2022. PMID: 34558232 Free PMC article. - Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia.
Sorrentino VG, Thota S, Gonzalez EA, Rameshwar P, Chang VT, Etchegaray JP. Sorrentino VG, et al. Pharmaceuticals (Basel). 2021 Jul 4;14(7):641. doi: 10.3390/ph14070641. Pharmaceuticals (Basel). 2021. PMID: 34358067 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous